secwatch.observer — SEC 8-K summary
======================================

Issuer:     PHIBRO ANIMAL HEALTH CORP (PAHC)
CIK:        0001069899
Form:       8-K
Filed at:   2023-05-03T23:59:59+00:00
Accession:  0001558370-23-007861
Event type: earnings
Sentiment:  negative
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Phibro Q3 net income falls 43% to $10.0M; Animal Health sales up 11%
--------------------------------------------------------------------

- Q3 net sales $245.7M (+3% YoY); net income $10.0M (-43%); diluted EPS $0.25 (-43%); adjusted diluted EPS $0.29 (-13%).
- Animal Health segment net sales +11% to $164.4M; Mineral Nutrition -9% to $62.9M; Performance Products -17% to $18.3M.
- Adjusted EBITDA $27.4M (-2% YoY); free cash flow -$43M trailing twelve months (inventory build of $43M).
- Company reiterates FY2023 guidance: net sales $960M-$1B, adjusted diluted EPS $1.21-$1.31.
- Management notes recessionary pressure in Mineral Nutrition; opened new autogenous vaccine facility in Brazil.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1069899/000155837023007861/0001558370-23-007861-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1069899/000155837023007861/pahc-20230503x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-23-007861

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer